


Healthcare Industry News: ION Solutions
News Release - September 4, 2008
Q Pharma, Inc. Names Bryan Koslow Vice President of Sales and Marketing
MORRISTOWN, N.J.--(HSMN NewsFeed)--Q Pharma, Inc., the industry leader in FDA Regulatory and Compliance Solutions, announced today that Bryan Koslow has joined the firm as Vice President of Sales and Marketing. In this role, Koslow will lead the development and execution of Q Pharma’s Sales and Marketing efforts, as well as expand the company’s strategic relationships.Q Pharma recently announced the consolidation of CSSC Inc., Integrated Pharma Technologies (iPT), and Q Logistics. The newly combined entity will provide Pharmaceutical, Biotechnology, and Medical Device clients with a “one-stop-shop” for all its regulatory and compliance needs. “We recognize that global macroeconomic trends are forcing firms to focus on cost saving initiatives without sacrificing quality. By combining our ValidatION Solutions, PDMA, and Fulfillment groups under one umbrella, and adding a seasoned sales executive like Bryan Koslow, we are now uniquely qualified to meet the ever-changing needs of the FDA-regulated industries,” said Patrick Den Boer, Founder and CEO, Q Pharma.
Prior to joining Q Pharma, Koslow was the Vice President of Sales and Business Development for Sparta Systems and Regional Sales Manager for Kofax Image Products. Koslow holds bachelors degrees in Finance and Computer Information Systems from Hofstra University and an MBA in Accounting from Monmouth University.
About Q Pharma
Q Pharma is the industry leader in FDA Regulatory and Compliance Solutions. Since 1994, the company has focused on delivering a comprehensive suite of Validation, PDMA, and Fulfillment Solutions to the FDA-regulated industries. Additional information can be found at www.qpharmacorp.com.
For more information please contact Bryan Koslow at 22 South Street, Morristown, NJ 07960, 973-656-0011, bryan.koslow@qpharmacorp.com.
Source: Q Pharma
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
